Sensible Medical Innovation, which is developing a non-invasive device for monitoring congestive heart failure (CHF), has raised $7 million from the Genesis and Vitalife funds.
The company was founded in 2007 by Amir Ronen, CEO, Dan Rappaport, chief scientist, Amir Soroka, Nadav Mizrahi, and Shlomi Bergida. The product has been successfully tested on animals and is now ready for human trials.
According to the company, the imaging method it has developed for internal organs is based on "unique Israeli capabilities in information technology" which it is not yet revealing. The combination of medical and information technology fits the joint investment by Vitalife, which specializes in healthcare, and Genesis, which specializes in communications.
At present there is no non-invasive solution for monitoring heart failure. In recent years, implanted devices for this purpose have reached the market, including one developed by Rimon Medical, which was sold to Boston Scientific for $80 million.
Sensible Medical Innovation recently won a $500,000 grant from the Global Cardiovascular Innovation Center, which is led by the Cleveland Clinic in the US.
Published by Globes [online], Israel business news - www.globes.co.il - on June 24, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009